Frontiers in endocrinologyAug 28, 2026

Glucagon-like peptide-1 receptor drugs and Parkinson's disease risk in people with type 2 diabetes: a review and analysis of large patient data

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Aug 29, 2026

Abstract

A systematic review and meta-analysis evaluated the association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and Parkinson's disease risk using large-scale real-world data.

Parkinson's disease is a common neurodegenerative disorder with no effective disease-modifying therapies currently available.
GLP-1 receptor agonists are primarily used for managing type 2 diabetes but may offer neuroprotective effects based on preclinical studies.
Existing real-world evidence regarding the connection between GLP-1RAs and Parkinson's disease risk is inconsistent.
This review highlights the need for a comprehensive analysis of available data to clarify the potential relationship.

Simplified

Parkinson's disease (PD) is the second most common neurodegenerative disorder, yet effective disease-modifying therapies remain elusive. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used in the management of type 2 diabetes mellitus (T2DM), have shown neuroprotective potential in preclinical studies. However, real-world evidence on the association between GLP-1RAs use and PD risk remains inconsistent and has not been systematically synthesized. This systematic review and meta-analysis aimed to evaluate this association using large-scale real-world data.